ClinicalTrials.gg
CompletedNCT06461039Updated May 8, 2025

A Research Study Looking at How the Compound NNC0487-0111 Works With Birth Control Pills and Affects Emptying of the Stomach in Women Not Able to Become Pregnant

A Phase 1 interventional study of NNC0487-0111 A and NNC0487-0111 C in Obesity, sponsored by Novo Nordisk A/S. Completed at 1 site in Canada. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-05-08.

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Mar 2025, 1 year 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
43
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 207 studies in Obesity by Novo Nordisk A/S — 48 open to participants now, 66 under way, 26 of them phase 3. Obesity · Novo Nordisk A/S.

Enrollment
141st of 166
43 · median 138
Started
2024
with 21 others
Phase 1
85 of 207
22 open now
Registered
124th of 207
by date

Among the 207 studies in Obesity by Novo Nordisk A/S, this one is the 141st largest by enrollment of the 166 interventional ones that give a count, is one of 22 that started in 2024, is one of 85 in phase 1, and was the 124th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

48 of the 207 studies in Obesity by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:

43 more — sign in →

By country, each count listing its studies:

All 48 open studies →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 65 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 207 studies in Obesity by Novo Nordisk A/S, or all of them as a file.
02

Study summary

This study medicine NNC0487-0111 to improve the treatment options for people living with overweight and obesity or with type 2 diabetes. The purpose of the study is to investigate if NNC0487-0111 affects how effective birth control pills are. Participants will take 1-tablet once daily. The study medicine will taken orally for 18 weeks and then study medicine will be injected with a thin needle in a skin fold in the abdomen for 9 weeks.The study will last for about 35 weeks.

03

Conditions studied

  • Obesity

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Females of non-.
  • Age 18 - 65 years (both inclusive) at the time of signing the .
  • (BMI) between 25.0 and 39.9 kg/m\^2 (both inclusive) at screening.
  • Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, and clinical laboratory tests performed during the screening visit, as judged by the investigator.

Exclusion criteria

Exclusion Criteria:

  • Any disorder, unwillingness or inability which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.
  • Any for the use of the oral used in the study according to the Microgynon Product Information.
  • Use of prescription medicinal products or non-prescription drugs including any herbal medicine known to interfere with the metabolic CYP pathways, such as hypericum (St. John's Wort), ginseng, garlic, milk thistle, and echinaceae, within 14 days before screening.

Exceptions are routine vitamins, occasional use of acetaminophen, ibuprofen and acetylsalicylic acid, or topical medication not reaching systemic circulation.

  • History of major surgical procedures involving the stomach potentially affecting absorption of trial products (e.g. subtotal and total gastrectomy, sleeve gastrectomy, gastric bypass surgery) or current presence of gastrointestinal implant.
  • Presence of gastrointestinal disorders potentially affecting absorption of drugs or nutrients, as judged by the investigator.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    NNC0487-0111

    Participants will receive oral dosing of NNC0487-0111 and gradually will escalate from dose 1 to dose 2. The oral NNC0487-0111 treatment will be followed by s.c. NNC0487-0111 treatment with dose escalating from dose 3 to dose 4.

    Drug: NNC0487-0111 A · Drug: NNC0487-0111 C · Drug: Levonorgestrel 150 μg + Ethinylestradiol 30 μg (Oral contraceptive OC) · Drug: Acetaminophen - 500 mg/15 ml

Interventions

  • NNC0487-0111 A will be administered subcutaneously.

  • NNC0487-0111 C will be taken orally.

  • DrugLevonorgestrel 150 μg + Ethinylestradiol 30 μg (Oral contraceptive OC)

    Drug page: Levonorgestrel

    Levonorgestrel 150 μg + Ethinylestradiol 30 μg (Oral contraceptive OC) will be taken orally.

  • DrugAcetaminophen - 500 mg/15 ml

    Drug page: Acetaminophen

    Acetaminophen - 500 mg/15 ml will be taken orally.

06

What researchers measure

Primary outcomes

  1. The area under the ethinylestradiol plasma concentration time curve at steady state

    Measured as hours picograms per milliliter (h\*pg/mL).

    Time frame: Day 8 and Day 193

  2. The area under the levonorgestrel plasma concentration time curve at steady state

    Measured as hours picograms per milliliter (h\*pg/mL).

    Time frame: Day 8 and Day 193

Secondary outcomes

  1. Maximum ethinylestradiol plasma concentration at steady state

    Measured as picograms per milliliter (pg/mL).

    Time frame: Day 8 and Day 193

  2. Maximum levonorgestrel plasma concentration at steady state

    Measured as picograms per milliliter (pg/mL).

    Time frame: Day 8 and Day 193

  3. The area under the ethinylestradiol plasma concentration time curve at steady state

    Measured as hours picograms per milliliter (h\*pg/mL).

    Time frame: Day 8 and Day 135

  4. The area under the levonorgestrel plasma concentration time curve at steady state

    Measured as hours picograms per milliliter (h\*pg/mL).

    Time frame: Day 8 and Day 135

  5. Cmax,EE,SS, maximum ethinylestradiol plasma concentration at steady state

    Measured as picograms per milliliter (pg/mL).

    Time frame: Day 8 and Day 135

  6. Cmax,LN,SS, maximum levonorgestrel plasma concentration at steady state

    Measured as picograms per milliliter (pg/mL).

    Time frame: Day 8 and Day 135

  7. AUC1 area under the acetaminophen concentration-time curve following a standardised meal

    Measured as hours micro grams per milliliter (h\*μg/mL).

    Time frame: Day 1 and Day 186

  8. AUC2 area under the acetaminophen concentration-time curve following a standardised meal

    Measured as hours micro grams per milliliter (h\*μg/mL).

    Time frame: Day 1 and Day 186

  9. Cmax,para, maximum acetaminophen plasma concentration following a standardised meal

    Measured as micrograms per milliliter (μg/mL).

    Time frame: Day 1 and Day 186

  10. AUC3 area under the acetaminophen concentration-time curve following a standardised meal

    Measured as hours micro grams per milliliter (h\*μg/mL).

    Time frame: Day 1 and Day 128

  11. AUC4 area under the acetaminophen concentration-time curve following a standardised meal

    Measured as hours micro grams per milliliter (h\*μg/mL).

    Time frame: Day 1 and Day 128

  12. Cmax,para, maximum acetaminophen plasma concentration following a standardised meal

    Measured as micrograms per milliliter (μg/mL).

    Time frame: Day 1 and Day 128

07

Study locations

1 site
  • Altasciences Clinical Company, Inc
    Montreal, Quebec H3P 3P1, Canada
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2024 to primary completion in Mar 2025, 9 months.

Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 9 months is close to that.

Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2024
First posted
Jun 14, 2024
StartActual
Jun 14, 2024
Primary completionActual
Mar 16, 2025
CompletionActual
Apr 4, 2025
Last update
May 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06461039
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jun 14, 2024
Start date
Jun 14, 2024
Primary completion
Mar 16, 2025
Completion
Apr 4, 2025
Last update
May 8, 2025

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NNC0487-0111

Start the discussion